Effects of Intravenous Amino Acid Administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487 [OctreoTher™]) Treatment

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 1, 2004, Pages 35-41

  Bushnell, David ^a,b   Menda, Yusuf ^b   O'Dorisio, Thomas ^b   Madsen, Mark ^b   Miller, Sara ^a   Carlisle, Thomas ^a,b   Squires, Shayne ^b   Kahn, Daniel ^a,b   Walkner, Wayne ^a   Connolly, Mary ^c   O'Dorisio, Sue ^b   Karwal, Mark ^b   Ponto, James ^b   Bouterfa, Hakim ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Amino acids; OctreoTher

Indexed keywords

AMINO ACID; AMINOSYN; ARGININE; CREATININE; LYSINE; OCTREOTHER; OCTREOTIDE[1 PHENYLALANINE 3 TYROSINE][1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID YTTRIUM 90]; PENTETREOTIDE IN 111; SMT487; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREMS RADIATION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; FEMALE; FOLLOW UP; HOT FLUSH; HUMAN; KIDNEY FAILURE; MALE; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; SIDE EFFECT; SYNCOPE; VOMITING;

ADULT; AGED; AMINO ACIDS; ARGININE; CARCINOID TUMOR; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; LUNG NEOPLASMS; LYSINE; MALE; MENINGIOMA; MIDDLE AGED; OCTREOTIDE; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 12144286483     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497804773391658     Document Type: Article

References (24)

1. 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients. Cancer Biother Radiopharm 1999;14:477.
2. Otte A, Hermann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999;26:1439.
3. 90Y-DOTATOC) in the treatment of neuroendocrine tumors: A clinical phase II study. Ann Oncol 2001;12:941.
4. 90Y-DOTATOC. Eur J Nucl Med 1999;26(8):877.
5. 111In-DPTA-octreotide. Eur J Nucl Med 2001;28(12):1743.
6. Boerman OC, Oyen WJG, Corstens FHM. Between the Scylla and Charybdis of peptide radionuclide therapy: Hitting the tumor and saving the kidney. Eur J Nucl Med 2001;28(10):1447.
7. Bernard BF, Krenning EP, Breeman WAP, et al. D-Lysine reduction of indium-111 octreotide and yttrium-90 Octreotide renal uptake. J Nucl Med 1997;38(12):1929.
8. 90Y-Dotatoc: Dosimetric evaluations. J Nucl Med 2001;42(suppl):246P.
9. Hammond PJ, Wade AF, Gwilliam AM, et al. Amino acid infusion blocks renal tubular uptake of an indium-labeled somatostatin analogue. Br J Cancer 1993;67: 1437.
10. Barone R, DeCamps J, Smith C, et al. Metabolic effects of amino acids solutions infused for renal radioprotection. J Nucl Med 2000;41(suppl):94p.
11. Valkema R, De Jong M, Kooij P, et al. Effective and safe inhibition of renal uptake of radiolabeled peptides by combined lysine and arginine infusion. J Nucl Med 2001;42(suppl):37P.
12. Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med 2003;30:9.
13. Behr TM, Bene M, Kluge G, et al. Nephrotoxicity versus anti-tumor efficacy in radiopeptide therapy: Facts and myths about the Scylla and Charybdis. Eur J Nucl Med 2002;29(2):277.
14. Shen, S, DeNardo, GL, Yuan, A, et al. Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung, J Nucl Med 1994;35(8):1381.
15. Emami B, Lyman J, Brown A. Tolerance of normal tissue to therapeutic radiation. Int J Radiation Oncology Biol Phys 1991;21:109.
16. 90Y-DOTATOC. Eur J Nucl Med 2001;28(10):1552.
17. Robbins ME, Bonsib SM. Radiation nephropathy: A review. Scanning Microscopy. 1995;9:535.
18. Krochak RJ, Baker DG. Radiation nephritis. Urology 1986;27:389.
19. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27(3): 273.
20. de Jong M, Krenning E. New advances in peptide receptor radionuclide therapy. J Nucl Med 2002;43:617.
21. Boerman O, Oyen WJG, Corstens FHM. Radiolabeled receptor-binding peptides: A new class of radiopharmaceuticals. Semin Nucl Med 2000;30:195.
22. 90Y-SMT487 (OctreoTher™)? J Nucl Med 2000;41(5, suppl.):110P.
23. Bodei L, Cremonesi M, Zoboli S, et al. Receptor mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase 1 study. Eur J Nucl Med 2003;30:207.
24. Jamar F, Barone R, Mathieu I, et al. 86Y-D-Phe1-Tyr3-octreotide(SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med 2003;30:510.